{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Antiviral Considerations for Monkeypox Infection - USE CAUTION!

Activity Steps

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Select the indications and contraindications for prescribing tecovirimat.
  2. Identify the potential outcomes of monkeypox infection.
  3. Recognize the risks for contracting monkeypox infection.
  4. Define the protocol for the National Institutes of Allergy and Infectious Diseases tecovirimat clinical trial.

Learning Outcomes

Seventy-five percent of participants will demonstrate competency in clinical reasoning regarding the use of and the precautions associated with the antiviral tecovirimat for treating monkeypox by achieving a minimum score of 70% on the outcomes based posttest.
Price: $17.95


  • ANCC 1.5 CH
  • DC - BON 1.5 CH
  • FL - BON 1.5 CH
  • GA - BON 1.5 CH
  • NM - BON 1.5 CH
  • SC - BON 1.5 CH
  • WV - BOERN 1.5 CEH

Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, Georgia Board of Nursing, New Mexico Board of Nursing, South Carolina Board of Nursing, and West Virginia Board of Examiners for Registered Professional Nurses, #50-1223.

Test Code: CNS0123
Published: Jan/Feb 2023
Expires: 3/7/2025
Required Passing Score: 8/10 (80%)
Authors: Patricia Anne O'Malley, PhD, APRN-CNS
Categories: Infection , Virology